过量服用L-氨酸是2型糖尿病患者心肌损伤的潜在危险因素
Yan Chen1, Meng-Ting Dai1, Guo-Hua Gong2
1School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China.
World journal of diabetes
|June 9, 2025
概括
补充L-氨酸 (L-Arg) 在糖尿病中表现出混合作用. 虽然安全剂量改善了糖尿病老鼠的脂质样本和体重降低,但更高剂量通过增加血糖和炎症而加剧了心肌损伤.
科学领域:
- 内分泌学 在内分泌学.
- 心血管研究研究心血管研究
- 营养科学 营养科学
背景情况:
- 氨酸 (L-Arg) 是一种食补充剂和氧化前体,对心血管疾病和糖尿病有潜在的益处.
- 以前的研究表明,L-Arg对糖尿病管理有有益影响.
- 这篇文章评论了曼苏里等人发现的结果. 在"世界糖尿病杂志" (World Journal of Diabetes) 发表了一篇关于L-Arg的作用的文章.
研究的目的:
- 评估L-氨酸补充剂对糖尿病大鼠血糖,脂质水平,体重和心肌组织的影响.
- 为了比较不同L-Arg剂量对糖尿病和正常大鼠模型的影响.
- 为糖尿病患者提供关于L-Arg安全和潜在有害剂量范围的见解.
主要方法:
- 在正常和糖尿病老鼠模型中,以不同剂量 (0.5g/kg,1g/kg和更高) 给予L-阿尔金因.
- 监测血液中的葡萄糖和脂质水平.
- 评估体重变化和心肌组织损伤,包括炎症和氧化应激标志物.
主要成果:
- 在正常的老鼠中,L-氨酸适度增加了血糖.
- 在糖尿病大鼠中,L-氨酸显著增加了脂质水平,与之前的一些发现形成鲜明对比.
- 在糖尿病大鼠中,0.5g/kg L-Arg 的剂量改善了脂质配置文件,并降低了体重.
- 在糖尿病大鼠中,较高剂量 (≥1 g/kg) 的L-Arg通过增加血糖,炎症和氧化应激而加剧心肌组织损伤.
结论:
- 服用安全剂量的L-氨酸补充剂 (0.5g/kg) 对改善糖尿病大鼠的脂质状况和减轻体重有好处.
- 高剂量的L-氨酸 (≥1g/kg) 可能通过血糖升高,炎症和氧化应激加剧糖尿病患者的心肌损伤.
- 这些发现表明L-氨酸在糖尿病中具有剂量依赖的作用,突出显示了心肌疾病患者高剂量补充剂的风险.
相关概念视频
Coronary Artery Disease I: Introduction
3
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
3
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Angina IV: Management
3
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
3
Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Coronary Artery Disease II: Pathophysiology
3
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
3
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395


